HTAi_AM22_program_digital_website

Lifecycle Approach: Coming Together to Make it Happen

Thank You to All Our Sponsors and Exhibitiors PLATINUM SPONSORS HEALTH ECONOMICS and HEALTH TECHNOLOGY ASSESSMENT DIAMOND SPONSORS GOLD SPONSORS EXHIBITORS

oTaf kgionogdcare health care Our Mission: Taking care of good health care 1. care is effective for a reasonable price; Every person residing or working in the Netherlands is 2. care is decided on in collaboration between healthcare entitled to good care services from the basic health insurance package. The National Health Care Institute is a government professionals and patients; organization whose main task is to put together the basic 3. care is organized as close to the patient as possible; health insurance package. Our goal is that everyone in the 4. care is focused on prevention and health instead of Netherlands - rich and poor, young and old, healthy and sick - can receive good care. Now and in the future. on sickness, and it contributes to the self-reliance and resilience of the persons concerned. Action Plan: Appropriate Care Like in many other developed countries, the quality, A new way of conducting HTA affordability and accessibility of health care in the With principle 1 we intend to adapt our way of conducting Netherlands is under pressure due to an ageing population, Health Technology Assessment (HTA), in which there is workforce shortages and rising costs of new medicines and more room for a “lifecycle approach”. To facilitate this long-term care. This necessitates making different choices development, we are also actively investing in international together now to ensure good health care in the future. HTA collaborations such as EUnetHTA21 and H2020-HTx. Together with the Dutch Health Care Authority, we developed Join the conversation! four principles of “appropriate care” to guide such decision- Implementing a “lifecycle approach” in HTA in accordance to these making. In our view, appropriate care is defined as care that principles will be a real challenge. Visit our conference booth in the Expo complies with the following four principles: Hall to learn more about our international agenda and to let us know what you think about these principles and what needs to be done to put them in practice! https://english.zorginstituutnederland.nl www.linkedin.com/company/cvz/ https://twitter.com/zinlactueel

INTRODUCTION Introduction 5

INTRODUCTION President’s Welcome Dear Friends and Colleagues, These challenges include a lack of high-quality clinical effectiveness evidence, difficulties in estimating and On behalf of the HTAi Secretariat and the Board of assessing cost-effectiveness, and last but not least Directors, allow me to offer a warm greeting to all of ethical issues are often not considered. In addition, you who are with us online and here in Utrecht - a the policy and regulatory landscape for approving new breathtaking city known for its rich history and culture health technologies has changed dramatically, not alone that started as far back as 11,000 Before Christ. as a consequence of COVID-19. Let us discuss during the coming two and a half-day to what extent a lifecycle I would like to emphasize that we are a global, approach could address some of these challenges that professional society dedicated to making healthcare we pose as HTA community. more accessible, equitable and impactful. In this capacity, we have a responsibility to contribute to a We already had two days of amazing pre-conference better world and to commit ourselves to the goals of workshops and a wonderful welcome reception last peace, respect, equality, and freedom. The military night. Currently, we are looking forward to a spectacular invasion of Ukraine is a reminder, if we needed one, that program of keynote speeches. plenaries, sponsored peace is never to be taken for granted. symposia, panels, poster and oral presentations all featuring the world’s great minds in health technology We should not forget that humanitarian aid is still assessment. We are also offering specially curated urgently needed in Ukraine as well as in other countries entertainment and networking. The next few days will be that suffer from challenges such as civil wars, drought, an extraordinary gathering for all interested in HTA. pandemics, and of course, armed conflict. We stand with and support all our members that suffer from these It is a tremendous task to organize a hybrid meeting challenges. I am proud to be part of a Society which of this scale. We genuinely appreciate all the support advocates for peace and continues to build bridges and from the country’s various public and private sector connect everyone involved in the HTA process. organizations who helped organize this event. As such, and after two years of virtual annual meetings I’d like to thank all the HTAi staff who made this happen, due to the COVID-19 pandemic, I am excited and including many volunteers. I am also very grateful to grateful that HTAi is convening its first “hybrid” meeting our 2022 Annual Meeting local host – Zorginstituut here in my home country, the Netherlands. This will Nederland (National Health Care Institute) and all our be an opportunity for the HTAi community to come sponsors for their strong support in these extraordinary together both in-person and online for extraordinary times, particularly when we moved from a virtual to a discussions of the theme of this year’s annual meeting: hybrid meeting. a lifecycle approach to determine the value of health technologies. I also would like to thank the International Scientific Program Committee under the wonderful leadership We all are aware that the COVID-19 pandemic not of the Co-Chairs Ann Single from Patient Voice only presented serious challenges for health systems Initiative, Australia also being the Chair of HTAi’s and wider economies around the globe; it also created Patient and Citizens Interest Group, Dr. Wim Goettsch challenges to health technology assessment bodies from Zorginstituut Nederland & Utrecht University, in determining the value of COVID-19 interventions.

INTRODUCTION Netherlands and Professor Gert Jan van der Wilt from stakeholders, is clearly reflected in the new definition Radboud university medical centre, Netherlands. They of HTA. It also conveys my conviction that integrating really have done a great job in concluding an amazing empirical analysis and normative inquiry in a transparent and exciting programme on a challenging topic. way are inherently in the best interest of the public. I extend my gratitude to the Local Organizing Thank you and I look forward to connecting with you Committee and its Co-chairs: my esteemed colleagues and learning from you! Professor Diana Delnoij from Zorginstituut Nederland (National Health Care Institute), Professor Aukje Mantel- Truly yours, Teeuwisse from Utrecht University and Professor Patrick Jeurissen from Radboud university medical centre. We Dr. Wija Oortwijn hope that you feel the Dutch flavour at the meeting, and HTAi President as the flowers. I hope that our Annual Meeting will be an engaging and enlightening opportunity for all of you with an interest in HTA to gather as a community of peers and reflect on how a Lifecycle approach can shape the future – all in service of better evidence, better methods, and better decisions for patients. Enjoy the opportunity to reconnect with old friends and colleagues, engage in lively discussions and debates, let off some steam, and make new connections. I hope that after the meeting, you feel both informed and motivated in your future work. And please share your experience throughout the meeting on social media with the hashtag #HTAi2022Utrecht Finally, I would like to end with a statement from Benjamin Franklin, an eighteenth-century scientist and founder of the American Philosophical Society. He initiated this Society in 1743 for the purpose of “promoting useful knowledge” and he stated the following: “Tell me and I forget, teach me and I remember, involve me and I learn.” His spirit of inquiry, providing a forum for the exchange of knowledge and views between all relevant 7

INTRODUCTION Local Organizing Committee Co-Chair’s Message Meeting provides an important platform to discuss the ways this can be accomplished and we look forward to Dear Friends and Colleagues, the ideas put forth by the participants of this conference! On behalf of the Local Organizing Committee (LOC), In addition to the pandemic, the conflict in Ukraine has it is our great pleasure to welcome you to the Health drastically changed the world in the last few months. Technology Assessment international (HTAi) 2022 The conflict serves as a stark reminder that the freedoms Annual Meeting, and to the beautiful city of Utrecht! and principles promulgated by liberal democracies over the last 75 years (e.g. tolerance of difference, We would like to take this opportunity to thank all respect for individual- and human rights, rule of law) those involved in the planning and organization of this are more fragile than anticipated. Our thoughts are with year’s meeting. In particular we wish to thank the HTAi those affected by the conflict. Most importantly, since Team, members of the International Scientific Program accessibility to care is a fundamental human right we Committee (ISPC) and the Local Host Organization, hope the conflict will be resolved quickly and peacefully, Zorginstituut Nederland, for their efforts. After two so that we can once again work together with our HTA virtual editions, the meeting in Utrecht will be hybrid. We colleagues towards that goal. look forward to connecting with old (and new) friends and colleagues. We hope you will enjoy your time at the Annual Meeting and that you will make the most out of the Scientific and With Utrecht as our venue, we have an inspirational Social Program - we look forward to meeting you there! backdrop for the conference. Located centrally in the Netherlands, Utrecht has a rich and vibrant history Prof. Diana Delnoij dating back to the Roman Empire. During and after the Departmental Head Research & Development and reformation, it was both a strategically important city for International Affairs commerce as well as a safe-haven for those sheltering from (religious) oppression and war in other parts of Prof. Aukje Mantel-Teeuwisse Europe We hope the delegates of the conference will University, the Netherlands feel at home and we encourage them to explore the beautiful city center. Prof. Patrick Jeurissen Professor Sustainable Healthcare Systems, Radboud We realize the Annual Meeting will take place during University tumultuous times. For over two years healthcare systems across the world have operated in a crisis mode and while the immediate crisis might seem over, the backlog of outstanding care will continue to put strain on systems already under pressure due to aging populations, workforce shortages and rising costs. Such circumstances necessitates decisive action based on the best available knowledge, which HTA can and should provide. In doing so, HTA itself is developing by focusing on following healthcare innovations and assessing their added value throughout their lifecycle. The HTAi Annual

INTRODUCTION Local Organizing Committee Co-Chairs Centre of Pharmaceutical Policy and Regulation. The Centre works closely together with WHO HQ, WHO Collaborating Prof. Diana M.J. Delnoij, PhD Centres and a wide range of other stakeholders in the field of Departmental Head Research & pharmaceutical policies and access to medicines. Her research Development and International interests include global health, pharmaceutical policy analysis, Affairs drug regulatory science, and variation in medicines use across countries. Diana Delnoij, PhD, is chief scientific officer of the National Health Care Aukje has been appointed Director of the School of Pharmacy Institute (0.7 FTE) and she holds an endowed chair as professor at Utrecht University since 1 July 2014. In this capacity she of Governing Healthcare Quality and Efficiency at the Erasmus is member of a number of (international) committees and School of Health Policy & Management (0.3 FTE). Diana is a working groups. political scientist with 35 years of experience in health services research. Prof. Patrick Jeurissen Professor Sustainable Healthcare As chief scientific officer she advises the National Health Care Systems, Radboud University Institute’s board and management on strategic R&D policy, and she is responsible for building networks with relevant Patrick Jeurissen, Ph.D., is a full-time academic and public partners, and external representation professor in fiscal sustainable health care in academic settings. In her academic work, she focuses systems at Radboud University Medical on topics such as governance issues in health technology School (0.8 fte) and Science Officer (0.2 fte) of the Ministry assessment, value-based healthcare, and measuring quality of Health, Welfare and Sports in the Netherlands. Jeurissen is and outcomes of care from the patient’s perspective. an expert on the design and implementation of policies that specifically address issues of sustainability and affordability of Internationally, Diana is active as chair of the International health care systems. He has (co)-authored some one-hundred Horizon Scanning Initiative (IHSI), a member of the NIHR scientific publications, and was a co-editor of two books on Applied Research Collaboration West Midlands Scientific the subject; he is also a sought speaker on (inter)national Advisory Group, and as editor of the European Journal of forums. Patrick represents the Dutch government at OECD. Public Health. He also has been an advisor for EU, WHO, OECD, and different governments across Europe on issues of healthcare reform Prof. Aukje Mantel-Teeuwisse and fiscal sustainability. His major interests are: strategic Prof. of Pharmacy and Global policymaking, health care finance and cost-containment Health, Utrecht University policies, for-profit providers and payers, solidarity in health care systems, hospitals, and comparative health care system Aukje is a professor of Pharmacy research. Currently, his focus within these areas is on tertiary and Global Health at the Division of care, multimorbidity, and administrative costs. He holds a Ph.D. Pharmacoepidemiology and Clinical in health economics, his dissertation covers for-profit hospital Pharmacology of Utrecht University. The Division is part of ownership in the US, the UK, Germany, and the Netherlands, the Research Network Health Technology Assessment & and holds an M.P.A., both from Erasmus University in Appraisal, a collaboration between UU, the National Health Rotterdam. Care Institute and ESHPM (Erasmus University). At present, she is also the Scientific Director of the WHO Collaborating

INTRODUCTION Members • P rof. Dr. Ton de Boer, Chair Medicines Evaluation Board, CBG en Utrecht University, Netherlands • Dr. Mariëlle Snijders, Departmental Head Efficiency Research (Doelmatigheidsonderzoek), ZonMw, Netherlands • Dr. Hanneke van Dongen, Assistant Professor Economic Evaluations of Healthcare, VU Medisch Centrum, • Prof. Dr. Ardine de Wit, Health economist and endowed Netherlands Professor, Senior Researcher/Health Economist (& Associate Professor UMC Utrecht), National Institute • Dr. Cor Oosterwijk, Director, VSOP Nederland, for Public Health and the Environment (RIVM) & Vrije Netherlands Universiteit Amsterdam, Netherlands • Prof. Dr. Michel van Agthoven, Director External • Mr. Ruud Koolen, Director, Utrecht Health Hub, Affairs, Janssen, Netherlands Netherlands Local Host Project Management • D r. Xavier Pouwels, Post-Doctoral Researcher, Universiteit Twente, Netherlands • Mr. Maarten de Haan, Project Manager HTAi 2022, Zorginstituut Nederland • Dr. Linetta Koppert, Oncological Surgeon / Clinical Epidemiologist, ErasmusMC, Netherlands • M r. Jeroen Duijvestjn, Communication Officer, Zorginstituut Nederland • Mrs. mr. Linda Daniels - van Saase, Manager, NPF, Netherlands • Dr. Hedi Schelleman, Observer, Zorginstituut Nederland • Dr. Leo van Rossum, Strategic Policy Advisor, Nederlandse Huisartsen Genootschap, Netherlands The Institute of Health Economics is wishing all HTAi delegates productive learning and engaged debate on lifecycle HTA Scan the code to learn more 10

INTRODUCTION International Scientific Program Committee (ISPC) Co-Chairs’ Message or online. Together we form a multi-disciplinary, multi- stakeholder community from around the lifecycle and HTAi 2022 Hybrid Annual Meeting– ‘Lifecycle globe that can thrive on our diversity of knowledge, Approach: Coming Together to Make it Happen’ experience and perspectives. In line with this, we’re pleased to share that this year’s program has a strong After months of cautious optimism, we write this contribution from people from low- and middle- welcome with excitement and gratitude as we begin to income countries. We also have more patients, and their believe that many of us will actually come together in representatives, than ever in attendance, including a person for HTAi Annual Meeting after three difficult years patient representative speaker in all three plenaries and apart. Furthermore, our gathering will not be limited to patients presenting on many panels. those able to travel to Utrecht but will include the active participation of anyone able to join virtually. Since we met To structure our thinking about a lifecycle approach to in Cologne, we’ve experienced the isolation and despair HTA we have developed three sub-themes: wrought by the Covid-19 pandemic. We may also have witnessed the value of collaboration and our perceptions • Adopting a Lifecycle Approach in HTA: Consequences of what is possible may have been re-framed. for Priority-Setting and International Collaboration ‘Coming together is key to this year’s theme of a lifecycle • Public Confidence in Healthcare Decision-Making approach to HTA. It’s an approach that reflects the idea that a one-off HTA can be insufficient for understanding • Running Around in Circles; Time for Real Collaboration the changing value of technology as it moves from between Regulators, HTA Bodies and Clinicians. pre-market, market approval, post-market and eventual disinvestment in a shifting health and evidence landscape. We thank the members of the International Scientific It’s been suggested that this approach should entail Program Committee for working with us to create continuous dialogue and the exchange of knowledge a stimulating program to enable us to deepen our between all stakeholders while ensuring that better understanding of the consequences of a lifecycle outcomes for patients are central to the activities of HTA approach to HTA. We wish you a productive and fun bodies. meeting filled with unexpected insights, thoughtful Q&As, new connections with people and ideas, and a renewed If a lifecycle approach is to achieve those ambitions optimism for HTA and your role in its judicious use to and meet the challenges of innovative and novel improve people’s lives. technologies, we must find ways to bring together disparate stakeholders and data requirements. We must agree priorities, foster better international collaboration, and explore the potential consequences. With this in mind, we welcome new and familiar faces to HTAi 2022 Annual Meeting whether you are in Utrecht

INTRODUCTION HTAi 2022 International Scientific Program Committee (ISPC) Co-Chairs (NL) where he is leading a new H2020 consortium with fifteen partners around Europe, called HTx on new methods for Health Prof. Prof. Gert Jan van der Wilt Technology Assessment for personalized medicine (2019- 2024). Between 2010 and 2013, he was the Deputy Secretary Prof. Gert Jan van der Wilt (1958) received of the Medicinal Products Reimbursement Committee at the his Ph.D. in Neuroscience from VU Dutch National Health Care Institute. He is currently a Director University, Amsterdam. After an initial on the Board of HTAi (2019-2022). Before joining the National focus on basic science, he developed an Health Care Institute, he worked as a research manager for the interest in the broader social and ethical PHARMO Institute and was responsible for the coordination of implications of new developments in numerous pharmacoepidemiological and outcomes studies neuroscience, such as the grafting of fetal tissue in the brain for international offices of pharmaceutical companies such of patients with Parkinson’s disease. To pursue this further, as AstraZeneca, Novartis, Pfizer, and GSK. He has a Ph.D. he was visiting scientist at the Hastings Center (NY), and was in immunology and advanced education in (pharmaco)- appointed a post-doctoral fellow at the Institute of Ethics of epidemiology and pharmaco-economics. He has more than VU University, Amsterdam. In 1994, he joined the Department 100 publications in peer-reviewed international journals. of Health Technology Assessment (HTA) of Radboud University, where he was appointed head (1996) and full professor of HTA Ms. Ann Single (2000). From 2000 to 2010, he also held a chair in interactive HTA at the Athena Institute for Innovation and Communication Ann became Chair of the HTAi Patient and in the Health Sciences at VU University, Amsterdam. He was Citizen Involvement Interest Group (PCIG) visiting scientist at the TC Chan School of Public Health, Harvard in 2019 after being an active member University (2018), and a fellow of the Institute of Advanced Study of PCIG since 2006. Her interest in this of Durham University, UK (2019). He served on the National area began when she directed patient Appraisal Committee of the Netherlands and was vice-chair involvement and communication in Scotland’s first HTA body of the Population Screening Committee of the Dutch Health and later established involvement processes for the Scottish Council. He was co-chair of the Interest Group on Ethics of Medicines Consortium. She is co-editor of the first book in the HTAi, and a member of HTAi’s Scientific Development and field, Patient Involvement in Health Technology Assessment Capacity Building committee. He participated in the EU-project (2017). Her current wider work includes provide training and INTEGRATE-HTA and coordinated the VALIDATE project, support for patients wanting to engage with HTA in Australia, funded by the Erasmus+ program of the EU. His main research co-developing and trialling a mentoring program for consumer interest is in the interplay of facts and values in the evaluation of members on Australian HTA committees, and contributing to healthcare technologies. PCIG projects on impact as well as patient participation at the organizational level in HTA bodies. Ann recently accepted an Dr. Wim Goettsch invitation to serve as a patient representative on the Reference Committee for the Australian Government’s HTA Policy and Dr. Wim Goettsch, Ph.D. is currently Special Methods Review. Advisor HTA at the Dutch National Health Care Institute He was the Director of the EUnetHTA JA3 (2016-2021). Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since 2019, he also has had a position as an Associate Professor at Utrecht University 12

INTRODUCTION Members • Dr. Rosmin Esmail, Provincial Trauma Epidemiologist, Alberta Health Services, Canada • Dr. Andres Pichon, Executive Director, Argentina  • Mr. Ken Bond, Director, HTA and External Relationships, • Mr. Meindert Boysen, Director of the Centre for Health Institute of Health Economics, Canada Technology Evaluation, National Institute for Health and Care Excellence, UK • Prof. Guy Maddern, RP Jepson Professor of Surgery, University of Adelaide, Australia • Dr. Claudia Wild, Chief Executive, AIHTA GesmbH • Ms. Dima Samaha, Principal, Real World Solutions, United • Mr. Parashar Pate, Senior Vice President, Government Affairs Kingdom & Market Access, ViewRay Inc., USA • Dr. Joice Valentim, Global HTA Strategy Lead, Roche • Prof. Tracy Merlin, Professor / Director, AHTA; Interim Head, School of Public Health, Australia  • Mrs. Ursula Giedion, Coordinator, Global HTA Strategy Lead, Roche • Prof. Rabia Kahveci, Senior Technical Advisor, SafeMed, Ukraine  • Dr. Alric Ruether, Head of International Affairs, Institute for Quality and Efficiency in Health Care (IQWiG), Germany • Mrs. Nuriya Musina, Associate Professor, Center of Healthcare Quality Assessment and Control, Russia • Dr. Izzuna Mudla Mohamed Ghazali, Deputy Director, Malaysian Health Technology Assessment Section (MaHTAS), • Dr. Iga Lipska, Hospital Based HTA Project Leader, National Medical Develoment Division, Ministry of Health, Malaysia Health Fund, Poland • Dr. Aurelio Meija, Director of Regulation Ministry of Trade, • Ms. Maoling Wei, The Center for Evidence-based Medicine Industry and Tourism, Colombia and Clinical Epidemiology, West China Hospital, Sichuan University, China • Dr. Jo Carol Hiatt, Vice President, Medical Device Innovation Consortium, United States • Dr. Armina Padmasawitri, Lecturer, School of Pharmacy, Institut Teknologi Bandung, Indonesia • Dr. Jon Campbell, SVP For Health Economics, ICER, USA • Dr. Ryota Nakamura, Professor, Hitotsuhashi Institute for • Dr. Mouna Jameleddine, Director, HTA Department, INEAS, Advanced Study (HIAS) Health, Japan INAHTA, Tunisia • Prof. Dr. Judith E. Bosmans, Professor, Vrije Universiteit Technical Officer Medical Center, Netherlands • Dr. Saskia Knies, Senior Advisor, National Health Care • Dr. Massoud Toussi, Senior Principal, Real World & Analytics Institute (Zorginstituut Nederland), Netherlands Solutions, IQVIA, France • Mr. Ivett Jakab, President, EPF Youth Group and Syreon Research Institute, Hungary • Prof. Chiara de Waure, Associate Professor, University Perugia, Italy

INTRODUCTION About HTAi Health Technology Assessment international (HTAi) is Membership a global, non-profit, scientific, and professional society for all those who produce, use or encounter health HTAi is a member-driven organization that represents technology assessment (HTA). We are an open platform a variety of stakeholders who have interests in HTA, for global collaboration that leverages and shares including researchers, policy makers, industry, academia, collective intelligence to improve health outcomes health service providers, agencies, and patients who worldwide - making health care more accessible, more contribute to the balanced conversation around HTA equitable, and more impactful. HTAi was founded in across different areas of practice and jurisdictions. 2003 and has since contributed to the global health ecosystem and HTA learning through our international HTAi members share a commitment to extending the Annual Meetings, Policy Forums, Interest Groups, journal conversation beyond the traditional bounds of industry publications, and more. or professional bodies by including those impacted by the conversations, and those whose decision making is influenced by the outcomes of HTA research. Our broad community of members use HTAi as an open platform for collaboration, as we all seek ways to use HTA to improve global health. HTAi Members benefit by having free online access to the International Journal of Technology and Assessment in Health Care, access to webinars and HTA resources and are welcome and encouraged to join one of our many Interest Groups.  Organizational Members are eligible for an invitation to our Policy Forums (Global, Latin America, and Asia) and our Annual Meeting is a draw for many of our members. These unique platforms allow members to participate in face-to-face discussions and be part of the critical conversations that help inform policy on the use of technologies in healthcare assessment. This collaboration ensures a balance of ideas from the broad HTA community. Our networking and partnership opportunities have been identified as truly unique by our members and we pride ourselves on bringing the world together to foster better healthcare through HTA. This collaboration ensures a balance of ideas from the broad HTA community. Our networking and partnership opportunities have been identified as truly unique by our members and we pride ourselves on bringing the world together to foster better healthcare through HTA. 14

INTRODUCTION HTAi Board of Directors 2022-2024 Directors President Vania Canuto Dr. Wija Oortwijn Brazil Netherlands (2020-23) (2021-23) Dr. Wim Goettsch Vice President Netherlands Dr. Rabia Kahveci (2019-22) Ukraine (2021-23) Dr. Catherine Holliday Switzerland Treasurer (2019-22) Dr. Marco Marchetti Italy Debjani Mueller (2021-24) South Africa (2019-22) Secretary Dr. Jo Carol Hiatt Dr. Leonor Varela-Lema USA Spain (2021-24) (2019-22) Past President Dr. Franz Waibel Dr. Iñaki Gutierrez-Ibarluzea Switzerland Spain (2020-23) (2021-23) Dr. Li Ying (Grace) Huang Taiwan (2020-23) Board Observers Policy Fora Chairs Prof. Wendy Babidge Dr. Dan Ollendorf Australia USA, HTAi Global Policy Forum Chair (2020- Editor-in-Chief, International Journal of 22) Technology Assessment in Health Care Dr. Manuel Antonio Espinoza Prof. Tracy Merlin HTAi Latin America Policy Forum Chair Australia (2022-24) INAHTA Prof. Guy Maddern HTAi Asia Policy Forum Chair (2022-24)

INTRODUCTION Interest Groups As a member of HTAi, you are invited to join one or Disinvestment and Early Awareness (DEA) more of the ten Interest Groups to share international • Chair: Rosmin Esmail (Canada) experiences and expertise among HTA users and • Co-Chair: Nora Ibargoyen Roteta (Spain) producers worldwide. • T echnical Officer: Anna Lien Espeland (Norway) The ten Interest Groups currently housed at HTAi are: Early Career Network (ECN) • Co-Chair: Maoling Wei (China) • D isinvestment and Early Awareness • Co-Chair: Denny John (India) • D eveloping Countries • Technical Officer: Vacant • E arly Career Network • Ethical Issues in HTA Ethical Issues in HTA (ETH) • H ospital-Based HTA • Chair: Ken Bond (Canada) • I nformation Retrieval • Co-Chair: Dario Sacchini (Italy) • M edical Devices • Technical Officer: Sylvia Nabukenya (Uganda) • Patient and Citizen Involvement • Public Health Hospital-based HTA (HB-HTA) • Real World Evidence and Artificial Intelligence • Co-Chair: Americo Cicchetti (Italy) • Co-Chair: Marco Marchetti (Italy) The Interest Groups (IGs) serve as professional and • Technical Officer: Vacant scientific fora for all those who undertake and use HTA in health care, business, government, academic HTA in Developing Countries (DCIG) institutions, and consultancies. • Chair: Jani Mueller (South Africa) • Technical Officer: Yves Miel Zuniga (Philippines) HTAi members can utilize the unique experience created by the Interest Groups and can network and exchange Information Retrieval (IRG) information, or even collaborate on projects. • Chair: Ingrid Harboe (Norway) • Co-Chair: Amanda Hodgson (Canada) IG members share topic updates, participate in the • Technical Officer: Gabriela Vilela de Brito (Brazil) development of new research and useful material, and develop workshops and training sessions. There are also opportunities for IG members to be involved in activities directly funded by HTAi. Please feel free to attend any of the IG Business Meetings. This will be held in concomitance to the Annual Meeting. Should you wish to join a specific Interest Group’s listserv, please send the request to [email protected].

INTRODUCTION Medical Devices (MDIG) Public Health (PHIG) • Chair: Richard Charter (Switzerland)) • Chair: Maarten Postma (Netherlands) • Co- Chair: Anastasia Chalkidou (UK) • Technical Officer: Vacant • Technical Officer: Victoria Hurtado (Chile) Real World Evidence and Artificial Intelligence Patient and Citizen Involvement (PCIG) (RWE-AI) • Chair: Ann Single (Australia) • Technical Officer: Veronica Lopez-Gousset (France) • Chair: Massoud Toussi (France) • Co-Chair: Dimitra Lingri (Greece) • Co-Chair: Elena Petelos (Netherlands) • Technical Officers: Alessandra Blonda and Sophia Valaris Insight meets 5/25/22 2:20 PM action at the point of possibility. Getting the most out of your robotics program—that’s Intuitive Learn more at intuitive.com Important safety information For Important Safety Information, indications for use, risks, full cautions and warnings, please refer to www.intuitive.com/safety © 2022 Intuitive Surgical Operations, Inc. All Rights Reserved. PN1097904-US RevB 05/2002 PN1097904-rB_APoP_DataViz_7-5x4in_R1.indd 1

INTRODUCTION HTAi Policy Forums Launched in 2003, and having since expanded, HTAi Findings from the most recent Policy Forums will be currently hosts three Policy Forums throughout the year: presented at this Annual Meeting during the following the Global Policy Forum (GPF), the Asia Policy Forum panel sessions: (APF) and the Latin America Policy Forum (LATAM PF). Each Forum is by invitation only, bringing together some HTA 2025 and Beyond: Lifecycle Approaches to of the most senior representatives in the field of HTA Promote Engagement and Efficiency in Health to participate in strategic discussions surrounding the Technology Assessment (2022 Global Policy Forum) present state of HTA and its development around the world. The Forums provide the opportunity to interact Monday, June 27 and network with various stakeholders on a one-on-one 14:20 – 15:35 basis, have open group discussions around relevant and pertinent topics, and have direct impact on local HTA Deliberative Processes for Informed Decision Making policies. by Health Technology Assessment (2021 Latin America Policy Forum) Topics discussed at the Policy Forums are diverse and Monday, June 27 complex, considering the pressing policy issues for 17:15 – 18:30 HTA. Past Forums have tackled topics such as: Lifecycle Approaches in HTA, Sustainability of Healthcare Systems HTA in Asia Post-COVID-19 (2021 Asia Policy Forum in Asia, and Stakeholder Involvement in the Health Tuesday, June 28 Technology Assessment Process in Latin America. Reports 16:55 – 18:10 from all the Policy Forum meetings are published in the society’s official journal, the International Journal of For more information or questions regarding the Policy Technology Assessment in Health Care (IJTAHC). Forums, please contact our Events Manager, Ali Powers at [email protected]. at [email protected]. The Global Policy Forum will host a Business and Topic Scoping meeting for HTAi members on Sunday, June 26 from 09:00 – 12:00.

INTRODUCTION Partnerships HTAi is strongly committed to international collaboration. In addition to official relations status with the World Health Organization, we have signed formal Memoranda of Understanding with INAHTA, ISQua and EuroScan. HTAi also collaborates with organizational members and regularly works with other like-minded organizations. World Health Organization In January 2015, HTAi became a Nongovernmental Organisation in Official Relations with the World Health Organization. EuroScan EuroScan, the International Information Network on New and Emerging Health Technologies, is a collaborative network of member agencies for the exchange of information on important new and emerging health technologies, including drugs, devices, diagnostics, procedures, programs and settings. INAHTA The International Network of Agencies for Health Technology Assessment (INAHTA) is a network of 51 publicly funded HTA agencies that support health system decision making that affect over one billion people in 31 countries around the globe. INAHTA brings HTA agencies together to share knowledge and tools to strengthen their role as essential contributors to health outcomes and health system sustainability. ISQua The International Society for Quality in Health Care (ISQua) is a global organization with origins dating back to 1984. Its mission is to inspire and drive improvement in the quality and safety of healthcare worldwide through education and knowledge sharing, external evaluation, supporting health systems and connecting people through a global network that spans 100 countries and five continents. HTAsiaLink HTAsiaLink is a collaborative research network of Health Technology Assessment (HTA) agencies in the Asia-Pacific region established on September 2010. The network started with an aim to strengthen Health Technology Assessment (HTA) research efficiency by sharing HTA information, experiences, and resources within the members. HTAsiaLink also focuses on promoting HTA utilization, developing an efficient methodology for HTA, and encouraging HTA evidences implementation for Universal Health Coverage.

INTRODUCTION HTAi Secretariat The HTAi Secretariat is based in Edmonton, Alberta (CANADA), and provides professional strategic and managerial support to our Board of Directors, committees, and members, while executing all HTAi activities. Health Technology Assessment international (HTAi) 1280 5555 Calgary Trail, Edmonton Alberta T6H 5P9 [email protected] HTAi.org Rob Abbott Hana Price Executive Director Senior Events Coordinator [email protected] [email protected] Melissa Donecz Breanne Dickhout Manager of Finance Events Coordinator [email protected] [email protected] Denise Jarrett Bryce Doherty Annual Meeting Manager Technology Lead [email protected] [email protected] Antonio Migliore Gerardo Cea Manager of Scientific Initiatives Coordinator, Technology [email protected] [email protected] Ali Powers Evani Goll Events Manager Senior Coordinator, Membership [email protected] [email protected] Tatiana Hagerty Naomi Suwinski Senior Coordinator, Governance Communications Lead [email protected] [email protected] Amren Thakur Annual Meeting Committee Liaison [email protected] 20

GENERAL INFORMATION General Information 21

GENERAL INFORMATION General Information € 0.02, € 0.05, € 0.10, € 0.20, € 0.50, € 1 and € 2) and seven notes (€ 5, € 10, € 20, € 50, € 100, € 200 and € About Utrecht 500). Very few shops, restaurants, etc., accept the € 500 note. Small shops and supermarkets do not accept the Utrecht is the lively, beating heart of Holland. It was built € 200 and € 100 notes either. When you pay in cash, the around the Dom tower, which you can see from any point in amount is rounded off to the nearest € 0.05. the city, so there is no way you can get lost in the attractive, car-free city centre. Utrecht boasts beautiful canals with ATMs extraordinary wharf cellars housing cafés and terraces by the water. As well as the Dom tower, Utrecht boasts hundreds If you have a foreign bank card with a Cirrus logo you of other monuments that each contribute to the special can get money from an Automatic Teller Machine (ATM). atmosphere in this centuries-old university town. Some ABN AMRO bank ATMs also accept cards with the PLUS logo. Also check your card and the ATM for EDC, Dutch is the official language in the Netherlands, but most EC and Maestro logos. You can also use most credit Dutch people speak English and often a bit of German or cards to obtain money from an ATM. French as well. Gratuity For more information about Utrecht, visit the Netherlands tourism website: https://www.holland.com In The Netherlands, Value Added Tax and service charges are included in your check in hotels, restaurants, shops COVID-19 Information for Visitors to and taxis. Tips for extra service are always appreciated the Netherlands but not required. It is customary to give taxi drivers and waiters a tip of about 10 percent. Many public restRooms All COVID-19 related measures have been abolished have an attendant who is usually tipped EUR 0,50. in the Netherlands. The travel rules for entering the Netherlands have been eased as well. Electricity Travelers to the Netherlands coming from within the The voltage outlets in the Netherlands is 230 volts. Travellers EU/Schengen Area no longer require a test, proof of are advised to bring a power converter and an adapter for recovery or proof of vaccination. round tow-prong plugs with side grounding contacts. Travellers from outside the EU/Schengen area no Medical Information longer have to carry a negative test result, if one of the following applies: Their country of origin is on the We hope that everyone stays healthy during the Annual EU’s list of safe countries, they hold a valid vaccination Meeting, but accidents can happen and sometimes you certificate or recovery certificate. may need medical assistance. Medical care is very well organized in Holland. You can find up to date information and travel advice at https://www.government.nl. Insurance Money It is strongly recommended that those attending/ participating in HTAi 2022 purchase adequate coverage The official currency of the Netherlands is the Euro for health, travel and private liability insurance before (EUR) but foreign currency is readily exchange at the departing their home countries. The organizers will airport and all major banks. There are eight coins (€ 0.01, not accept responsibility for personal injury, loss or damage to private or personal property of conference attendants/participants and/or accompanying persons.

GENERAL INFORMATION Annual Meeting Dates • Tuesday, June 28 07:30 – 18:00 • Wednesday, June 29 08:00 – 11:00 Annual Meeting Dates Annual Meeting Timetable June 25-29, 2022 All HTAi 2022 Annual Meeting sessions will be held in the Annual Meeting Venue (In Person) Beatrix Building, Jaarbeurs. Please consult the program or the App for detailed timing of all sessions, meetings Beatrix Building, Jaarbeurs, Jaarbeursplein, 3521 AL and refreshment breaks. All references to time within Utrecht, Netherlands this program are noted in Central European Summer Time (CEST), UTC+2. Tel: +31 30 295 5911 Annual meeting App https://www.jaarbeurs.nl Download the HTAi 2022 App for the full Annual Annual Meeting Secretariat Meeting experience! The App is available for download free-of-charge at the Apple and Google Play stores. HTAi Annual Meeting Management: Once downloaded be sure to sign in using your HTAi HTAi Secretariat login and app code “htai-2022” to connect with your Health Technology Assessment international (HTAi) peers. 1280 5555 Calgary Trail, Edmonton Alberta T6H 5P9 [email protected], www.htai.org Exhibit Area Hours Access and Security The exhibit tables are located on the ground floor in the Expo Hall and will be open at the following times: Name badges will be provided to all delegates and participants at the Registration/Check-in Desk. The • Monday, June 27 10:00 – 18:00 badge is your admission pass to all Annual Meeting • Tuesday, June 28 09:30 – 19:00 sessions and the exhibit areas. Tickets will be printed and • Wednesday, June 29 08:00 – 14:00 provided for all social events. Delegates are required to wear their name badge at all times and will not be Posters granted access to the conference without them. This is to ensure tat access to the conference is properly Posters are displayed in the Expo Hall on digital poster managed. columns, on the virtual meeting platform and can be accessed through the Annual Meeting App. Facilitated Annual Meeting Registration/Check-in poster presentations are scheduled during lunch breaks Desk on Monday 27 and Tuesday 28 June. See the program for more details. The registration desk is located in the foyer of the Beatrix building on the ground floor and will be open Speaker Ready Room/Slide Preview during the following times: Room • Saturday, June 25 07:45 – 17:00 TThe Speaker Ready Room is available in Room 310 • Sunday, June 26 07:45 – 20:30 on the 3rd floor of the Beatrix Building. Pre upload of • Monday, June 27 07:15 – 19:00 presentations is mandatory, but speakers are requested to visit the Speaker Ready Room at least 2 hours before their presentation (or, if their session starts at 08:00,

GENERAL INFORMATION HTAi Annual Meeting App HTML5 App: Event Code: htai-2022 Install URL: https://htai. How to use the app: eventsair.com/attendeeapp/ htai-2022-utrecht-annual- 1. Install the app from one of the provided URL’s. meeting/htai-2022-utrecht 2. Open the app and input the event code htai-2022 IOS App: 3. Log in using your HTAi log in and app code or password. Install URL: https://itunes. apple.com/us/app/the- Navigating the App: event-app-by-eventsair/ id1142851582?ls=1&mt=8 Log In: This is where you can log in to the app to access the full benefits. Please use your HTAi log in information. Android App: Alerts: Any notices or alerts sent by the event organizer will be Install URL: https://play. found here. google.com/store/apps/ details?id=com.eventsair. Agenda: This is the full agenda for the HTAi Annual Meeting. attendeeapp While scrolling through sessions you can see timing, Room information, speakers, a description, polling, Q and A, and any hand outs. If a session interests you be sure to favourite it as well. My Agenda: This will only show sessions which you have favourited or starred. Meeting Hub: A way to connect with other event attendees and communicate. Sponsors: Where you can access information and materials provided by this years sponsors. Live Support: You have access to virtual support through the app. Select this to be in contact with one of HTAi’s Secretariat who is happy to assist you. FAQ: A short FAQ for the event. Privacy and Settings: Here you can adjust your privacy settings for the event app. Log Out: Log out of the app. 24

GENERAL INFORMATION by 18:00 the previous day) to ensure their upload is Photography, Audio and Video complete and displaying accurately. The Speaker Ready Recordings Room will be open at the following times By attending the HTAi 2022 Annual Meeting, the • Saturday, June 25 07:30 – 17:00 participant understands and provides consent to being • Sunday, June 26 07:30 – 18:00 photographed or being recorded by means of video or • Monday, June 27 07:30 – 19:00 audiotape recording by the Organizers, or a designated • Tuesday, June 28 07:30 – 19:00 representative of the Organizers. These photographs • Wednesday, June 29 07:30 – 09:30 and/or recordings can be used, without compensation to the Delegate, in any public display, publication or Annual Meeting Wifi media, or website, or in any manner or form, and at any time by the Organizers in promotion of the mission Complimentary wifi service is provided by the to promote the Annual Meeting. The participant conference and available through the common areas releases the Organizers, and their employees, agents, and meeting spaces of the Beatrix Building. representatives, associates, Board of Director members, and consultants from any liability in connection with the Lost property use of such photographic, video and/or audio materials. Any found items will be stored at the Beatrix Building Refreshment Breaks and Lunch reception desk. After the Annual Meeting, all found items will be placed on the following site: https://ilost.co/nl/ All refreshment breaks and lunch will be served in the org/jaarbeurs  Expo Hall (Ground Floor). For those attending sponsored symposia or business meetings during lunch breaks, a Annual Meeting Language pre-packed lunch bag can be collected from the 1st floor foyer. The official language of the HTAi 2022 Annual Meeting is English and all sessions will be conducted in English.

GENERAL INFORMATION Floor plans Beatrix Theatre - Ground Floor plan Ingang Jaarbeursplein podium lift lift Mies Bouwman Lift Lift Foyer Trap Registration vrije hoogte 2.70 m vrije hoogte onder koof 2.75 m Receptie Expo Hall Trap vrije hoogte onder koof 2.75 m Lift Lift Toilet dames Toilet heren vrije hoogte 2.70 m vrije hoogte 2.40 m 26

Beatrix Theatre - 1st Floor plan GENERAL INFORMATION Room Beatrix Theatre - 2nd Floor plan 117 21 116 21 lift lift registratie deuren Trademart deuren JFF 12 21 registratie lift lift 115 21 Room Room 114 215 110 210

GENERAL INFORMATION Beatrix Theatre - 4th Floor plan Beatrix Theatre - 3rd Floor plan Room 417 323 322 321 416 320 415 414 319 lift lift 412 411 318 317 lift lift lift lift 316 lift lift Room 315 311

GENERAL INFORMATION Virtual Annual Meeting Platform MY SETTINGS AND UPDATING YOUR PROFILE Guide to using OnAIR When you first sign on to the OnAIR platform, the Event Check-In window displays, prompting you to update OnAIR is an online hub where both in person and your personal profile. virtual attendees can connect and participate with the Annual Meeting content. The OnAIR app is useful for The ‘About You’ section includes the contact details that all attendees, both virtual and in-person. An annual were provided as part of your registration. Your name meeting attendee can look up the event’s agenda and email address cannot be changed as they are linked and session information, edit their profile information, to your account. In your ‘Profile’ you can add or update connect with other attendees in the meeting hub, take your picture, provide your biography as well as your part in the event gamification, look at the resource social media links. gallery, and watch virtual sessions through the OnAIR app. If you are viewing from outside of Canada, we strongly Both the OnAIR and annual meeting mobile app can suggest updating your time zone on this page to display communicate, as both offer many similar functions, the program on the OnAIR timeline in the correct time including agendas, profile updates and meeting hub. for you. Gamification, resource gallery and virtual sessions are exclusive to the OnAIR app. In ‘Privacy Settings’ you can decide how much or how little information you would like to share with other ACCESS attendees and ‘Media Settings’ allows you to control OnAIR app link: your camera and microphone. https://portalapp.htai.eventsair.com/ VirtualAttendeePortal/htai-2022-utrecht-annual- To edit or change these settings at any time, please click meeting/htai-2022-am on your profile photo at the top right corner of your OnAIR app QR code: screen and select ‘My Settings’. NOTE: Please use Google Chrome if accessing the LIVE SUPPORT OnAIR app via internet browser. When you first sign on to the OnAIR platform, the Event Check-In window displays, prompting you to update your personal profile. The ‘About You’ section includes the contact details that were provided as part of your registration. Your name and email address cannot be changed as they are linked to your account. In your ‘Profile’ you can add or update your picture, provide your biography as well as your social media links. If you are viewing from outside of Canada, we strongly suggest updating your time zone on this page to display the program on the OnAIR timeline in the correct time for you. In ‘Privacy Settings’ you can decide how much or how little information you would like to share with other attendees and ‘Media Settings’ allows you to control

GENERAL INFORMATION your camera and microphone. VIRTUAL EXHIBITION To edit or change these settings at any time, please click You can visit the Virtual Exhibition at any time during the on your profile photo at the top right corner of your event by clicking on the ‘Meet Exhibitor’ button on the screen and select ‘My Settings’. right side of the timeline. When you are in the Virtual Exhibition Hall, you can search and browse through the USING THE TIMELINE list of exhibitors. Clicking on the ‘View’ button lets you review the exhibitor’s information and download any Your starting point on the OnAIR meeting platform is available brochures. You can also choose to connect the timeline page. Centrally on this page, you can see all with members of the exhibitor’s team via Meeting Hub. the sessions and functions that are happening each day, If the exhibition is open and the exhibitor’s staff is online, listed in chronological order. You can click on any of you can request a live meeting and you will be placed the items in the timeline to view additional information in a queue. You can always see your position in the and join the session or function. From any page, you queue and when you reach the top of the queue a video can return to the timeline by selecting ‘Back To Timeline’ meeting with the selected member of the exhibitor’s displayed in the top left corner of your screen. team will begin. LIVE HOST ORAL AND POSTER PRESENTATION GALLERY At various times during the event, the ‘Live Host’ In the ‘Oral and Poster Presentation Gallery’, you will window may appear to provide further information be able to browse and search for presentations that about the event. You can choose to mute the ‘Live Host’ interest you. Click on the presentation to find out more by clicking on the volume icon and you can move or information and enter to view the recorded presentation. minimize the ‘Live Host’ window as needed. You can use the discussion forum, download presenter handouts and enter your own notes. JOINING A ZOOM WEBINAR SESSION (FOR PRESENTERS) MUTING YOUR CAMERA AND MICROPHONE When joining a Zoom webinar session, a window will When using the Meeting Hub, Live Support or Exhibitor appear asking you to use either your computer audio Instant Meetings, your camera and microphone will be or connect to the audio via telephone (dial-in details enabled by default once the Video Call starts. Click on are provided). If the webinar does not load or if you are the icons in the video window to disable the camera and having any technical issues viewing the session, please mute your microphone as needed. click on the ‘Live Support’ icon for additional assistance. EXPORTING YOUR NOTES AND CONTACTS USING THE MEETING HUB Any notes that you take throughout the event as well as The Meeting Hub allows you to connect and any contact details from your Meeting Hub connections communicate with other attendees. Once you have can be exported by selecting the ‘Export’ icon in the top located an attendee you want to connect with, click right corner of your screen near your Profile image. the ‘Connect’ button. Once the other attendee accepts your request, you can choose to interact with your HAVING CAMERA OR MICROPHONE PROBLEMS? connection by starting a live chat or live video call. You can also schedule to meet at a future time, send Please reset or review your browser permissions for messages and take notes. Contact information for all your camera and microphone. For example, in Chrome, attendees you have connected with will be included you can click on the small lock icon to the right of the when you export your contacts (see ‘Exporting your platform URL to check on these settings. Notes and Contacts’ for additional information).

SCHEDULE-AT-A-GLANCE Schedule-at- a-Glance 31

SCHEDULE-AT-A-GLANCE SScchheedduluel-eat--Aa-t-GAla-nGcelance HTAi Business Meetings Social Events Ceremonies Workshops Panels Plenaries Exclusive Symposia Oral Sessions Saturday 25 June Sunday 26 June Monday 27 June Tuesday 28 June Wednesday 29 June Opening Ceremony Plenary 2 08:00 Pre-Conference 08:00-08:40 08:10-09:25 David Banta Tribute & Workshop Keynote Award Presentation 09:00 Pre-Conference 08:30-10:00 08:40 - 09:00 Special Session 08:45-09:15 Workshop Plenary 1 09:25-09:40 Panels 5 08:30-10:00 09:00-10:15 Oral 3 09:25-10:40 09:50-11:05 10:00 Refreshment Break Refreshment Break Refreshment Break Refreshment Break 11:00 10:00-10:30 10:00-10:30 & Posters 1 10:15-10:45 Refreshment Break 10:40-11:10 Exclusive Symposium & Posters 6 11:05-11:35 Plenary 3 Pre-Conference Pre-Conference 10:45-12:00 Panels 3 11:10-12:45 Workshop Workshop 11:35-12:50 10:30-12:00 10:30-12:00 Oral 1 12:10-13:10 12:00 Lunch Lunch 12:00-13:00 12:00-13:00 13:00 Pre-Conference Pre-Conference Lunch / Posters 7,8,9 / Closing Ceremony Workshop Workshop Sponsored Symposia / IG 12:45-14:00 13:00-14:30 13:00-14:30 Meetings Lunch / Posters 2,3,4 / 12:55-13:55 Refreshment Break Sponsored Symposia / IG 14:00 14:30-15:00 Meetings 13:15-14:15 Oral 4 Pre-Conference 14:00-15:00 Workshop Panels 1 Refreshment Break 15:00-16:30 14:20-15:35 14:30-15:00 15:00 Exclusive Symposium Pre-Conference 15:10-16:25 Workshop 15:00-16:30 16:00 Oral 2 15:45-16:45 17:00 Refreshment Break & Refreshment Break & Posters 5 16:45-17:15 Posters 10 16:25-16:55 Panels 2 Panels 4 17:15-18:30 16:55-18:10 18:00 Welcome Reception IG Meetings 19:00 18:30-22:00 18:15-19:15 Annual General Meeting Conference Dinner 19:00-20:00 19:30-00:00 Please note that times may be subject to change.

FEATURE SESSIONS Feature Sessions 43

FEATURE SESSIONS Feature Sessions Sunday, June 26 Monday, June 27 Welcome Reception Welcome Ceremony and Keynote Address In-Person: 18:30 – 22:00 Mies Bouwman Foyer 08:00 – 09:00, Beatrix Theatre (Ground Beatrix Building, Utrecht Floor) Virtual: 18:45 – 21:00 Virtual Meeting Platform • Welcome address on behalf of the host & Mobile Conference App organizations, Dr. Sjaak Wijma, National Health Care Institute Netherlands Join us in welcoming colleagues and friends from around the world to the HTAi 2022 Hybrid Annual • Opening address from the Netherlands Director of Meeting. Enjoy some special entertainment and Medicine, Karla van Rooijen, Ministry of Health, the receive a warm welcome from our local hosts both Netherlands live in Utrecht and streamed to the virtual meeting platform. There will be plenty of time to network with • Welcome address on behalf of HTAi, Dr. Wija international attendees and start engaging conversations Oortwijn , HTAi President, the Netherlands to revisit throughout the Annual Meeting. • Welcome address on behalf of the HTAi 2022 ISPC, Dr. Wim Goettsch, Ann Single, and Professor Gert Jan van der Wilt • Keynote presentation, Prof. Marcel Levi Prof. Marcel Levi Chairman, Netherlands Organization for Scientific Research (NWO), The Netherlands Prof. Marcel Levi is an Internist and, since April 2021, the Chairman of the Netherlands Organization for Scientific Research (NWO) and Professor of Medicine at Amsterdam UMC and University College London. He was previously Chief Executive of University College London Hospitals and Chairman of the Board of Directors of the AMC. He previously worked in Perugia, Oxford, New York, and Leuven. He has published over 750 scientific articles and is a member of the Royal Academy of Sciences and an honorary fellow of the Royal College of Physicians. He holds board positions in national and international organizations in the fields of healthcare, research, and education/training.

FEATURE SESSIONS Monday, June 27 path to follow winding through these challenges and opportunities associated with the adoption of lifecycle Plenary 1 approach in HTA? Do adequate priority-setting and international collaboration and coordination help? This 09:00 – 10:15, Beatrix Theatre (Ground Floor) plenary will try to find out. Adopting a Lifecycle Approach in HTA: MODERATORS Consequences for Priority-Setting and International Collaboration Alric Rüther Head International Affairs Institute For HTA has recently been defined as Quality And Efficiency In Health Care (IQWIG), Germany “a multidisciplinary process that uses explicit methods to determine the value of a health Alric Rüther is a physician trained technology at different points in its lifecycle. The in Internal Medicine and Oncology. purpose is to inform decision-making in order to Based on his engagement in Evidence Based Medicine promote an equitable, efficient, and high-quality and Cochrane Collaboration, he worked to establish health system” (O’Rourke, Oortwijn and Schuller, Int and build the discipline of HTA in Germany. Alric is J Technol Assess Health Care 2020; 36: 187 – 190). founder of the German Agency for HTA (DAHTA) at DIMDI of the Federal Ministry of Health. In 2007, Alric Adopting such a lifecycle approach in HTA has a number moved to the Institute of Quality and Efficiency in Health of potentially far-reaching consequences. Rather than Care (IQWiG), heading the Department of Health Care a one-off exercise to critically appraise and synthesize Quality. His main task of the department was to identify the best available evidence to support market access and describe Health Care Standards based on Clinical and coverage decisions, it involves several tasks and Practice Guidelines, such as scientific background for requirements which continuously need attention. Disease Management Programs (DMP). Additionally, Alric Central, but not exclusive, is the careful monitoring of was responsible for the development and maintenance novel technological developments, the anticipation of the international relationships of IQWiG. This led to of their potential impact, and keeping track of their the establishment of the Department of International evolution, especially in terms of gaining or losing value Affairs at IQWiG in 2015, which Alric is leading now. as the result of (parallel) technological, epidemiological, Alric has been engaged in worldwide HTA development economic, organizational and cultural developments. for more than 10 years: with HTAi since its founding Hence, rather than focusing on individual technologies, (Board member since 2013; Chair of Annual Meeting a health system’s perspective will be needed. Consistent Committee from 2016 to 2017; Chair of Scientific consideration of the lifecycle will change the way Development and Capacity Building Advisory Committee research and policy interact and inform each other and since from 2017 to 2020); INAHTA (Vice Chair until affect the tasks of HTA agencies, both quantitatively and 2006; Chair of internal communications from 2005 to qualitatively. Diversification of methods will be needed, 2016); EUnetHTA (founding member; Chair of plenary as well as a re-thinking of what constitute relevant data from 2010 to 2012; Lead Partner Quality Management, and how these may be obtained (e.g., is organizing Scientific Guidance and Tools [WP6] Joint Action 3 from continuous data collection combined with AI-supported 2016, Co-Chair of the Consortium of EUnetHTA21 from analysis the key?). Appropriate scientific development 2021); and ISPOR (Chair of HTA roundtable Europe from and capacity building will be required and, because of an 2013 to 2016). Alric is also an associate professor at the increased workload for HTA agencies, setting priorities University of Bielefeld and Berlin, lecturing HTA. and international collaboration and coordination will be needed more urgently. What could be the best

FEATURE SESSIONS SPEAKERS Dr. Janneke Grutters Associate Assistant Professor, Dr. Jaap Deinum Departments of Health Evidence and Medical Specialist Internal Medicine, Operating Theater, Radboud University Department of Internal Medicine, Medical Centre, the Netherlands Radboud University Medical Centre, the Netherlands Dr. Janneke Grutters works as an associate professor at the Health Evidence and Dr. Deinum is an internist, with a focus Operating Rooms department at Radboudumc, on vascular medicine. He was trained in Rotterdam Nijmegen, the Netherlands. She holds an MSc in health (Erasmus MC), the Netherlands and registered in sciences and a Ph.D. in Health, Medicine and Life 1995. Since 2002, he has been a staff member at the Sciences from Maastricht University. department of Medicine at RadboudUMC, Nijmegen, the Netherlands Her key research interest lies in the early evaluation of innovations in healthcare. By assessing the Dr. Pauline Evers (potential) value of innovation in the early stages Patient advocate at the Dutch of its development, she aims to contribute to more Federation of Cancer Patient accountable decisions regarding the development, Organizations, Member of the research, and use of these innovations, leading to Committee for Orphan Medicinal more efficient use of resources and better healthcare. Products at the European Medicines Learning from other fields of research, she develops and Agency, the Netherlands uses methodology that enables such an early evaluation and acknowledges all relevant uncertainties. After studying medical biology at the University of Groningen, The Netherlands (1983), Dr. Evers conducted Since 2015 she has been awarded a junior Principal her Ph.D. in Anthropogenetics at the Free University Investigator predicate from Radboudumc for scientific of Amsterdam (1988). She worked for 15 years in the excellence and is a member of several committees pharmaceutical industry, mainly in regulatory affairs. of the National Health Care Institute (Zorginstituut Nederland) and the Netherlands Organisation for Health Since 2003 she has worked for various patient Research and Development (ZonMw). organizations, first in the rare disease area at the VSOP (the Dutch umbrella organization for rare and inheritable Dr. Izzuna Mudla Mohamed Ghazali diseases) and ENMC (European NeuroMuscular Centre) Deputy Director, Malaysian Health and since 2008 at the Dutch Federation of Cancer Technology Assessment Section patient organizations (N.F.K.). Her advocacy activities are (MaHTAS), Ministry of Health Malaysia, in medicinal products, research, and reimbursement. Malaysia Since May 2006, she has been one of the three patient Dr. Izzuna Mudla Mohamed Ghazali is representatives on the Committee for Orphan Medicinal the Deputy Director of Medical Development Division, Products (COMP) at the European Medicines Agency Ministry of Health Malaysia and the Head of Malaysian (E.M.A.). Health Technology Assessment Section (MaHTAS). She is a Public Health Physician and joined MaHTAS in 2007. Since then, she has been involved in planning and implementation of health technology assessment, development and implementation of clinical practice

FEATURE SESSIONS guidelines, and was given the responsibility to set up Johns Hopkins University in the USA. Her interests span horizon scanning of emerging health technologies several areas of health economics and health services activity for Ministry of Health Malaysia in 2013. She research. became the Head of Horizon Scanning, Communication and Information Unit at MaHTAS until 2020. Dr. Izzuna Mr. Markus Siebert is actively involved at local and international level. She Senior Director, Health Economics and is a visiting lecturer at University of Malaya, University Reimbursement OUS, Abbott, Belgium of Science Malaysia and Cyberjaya University. She is also member of various committees at national level Markus Siebert is the Senior Director of including Cluster of Emerging Technologies, Nutritional Health Economics & Reimbursement Research, National Technology Innovation Sandbox of the and National Rare Disease Committee. At international level, she is currently the Vice President of HTAsiaLink, International Division at St. Jude Medical (now Regional Coordinator for AsiaScan, the regional group Abbott) since January 2012. He is responsible for the for Asia Pacific region of the International Health development and execution of reimbursement strategies TechScan (i-HTS) and a member of the organising and for guiding the development of health economic committee for HTAi Asia Policy Forum. She has also evidence in support of Market Access for Abbott’s published several articles on public health matters and medical device innovations in Europe, Latin America, health technology assessment. Asia and Australia. Dr. Susan Myles Markus works with multiple stakeholders, including Director, Health Technology Wales, payers and HTA agencies to establish and improve United Kingdom reimbursement for Abbott’s innovations. He is also driving internal initiatives on Early Value Assessment and Susan Myles is Director of Health Market Access for Digital Solutions. Technology Wales (HTW) a national HTA body established to deliver a Markus has held several positions at MedTech Europe strategic approach to the identification, appraisal, and (previously Eucomed), the European medical technology adoption of medical technologies in Wales (UK). HTW association. He served as Chair of the Evidence & Payers produces rapid evidence reviews and national guidance Working Group and as Chair of Working Groups on on the use of medical technologies in health and care Economics and Telemonitoring. He was a member of settings in Wales. Susan has been engaged in applied the Cardiovascular Roundtable of the European Society health technology assessment for 25 years. Prior to of Cardiology; and a company representative on the joining HTW, she led the establishment and work of the HTAi Policy Forum. Markus was co-initiator and Board Scottish Health Technologies Group (SHTG). Member of EHTI, the European Health Technology Institute for Socio-Economic Research and has co- Susan holds qualifications in Economics (BA, Strathclyde) authored several publications in the area of medical Health Economics (MSc, York) Epidemiology (PgDip, device market access. Edinburgh) and Health Services Research (PhD, Edinburgh). She has held lectureships and research Markus joined St. Jude Medical in January 2004 after positions in health economics and received scholarships almost seven years at Eucomed (now MedTech Europe), from the UK Department of Health and Medical where he headed the Economic Affairs Department. Research Council. Susan is also a previous recipient of a Harkness Fellowship in Healthcare Policy, based at He holds a Master’s Degree in Economics from the University of Bochum (Germany) and a Master’s in Health Economics from VLEKHO, Belgium. 47

FEATURE SESSIONS Tuesday, June 28 jurisdictions and assesses and reassesses value in different settings and cultures. Amongst this potentially Plenary 2 increased diversity of world views, can shared values be found to support public confidence? What processes 8:10 – 09:25, Beatrix Theatre (Ground Floor) can support the continuous dialogue imagined among stakeholders in a lifecycle approach? Will processes Public Confidence in Healthcare Decision- to integrate stakeholder perspectives support wider Making confidence in procedural justice? Who will agree the priorities? How will power differences be managed? The legitimacy of healthcare decision-making has never been so fiercely debated as in the COVID19 Since its conception, HTA has invested heavily in pandemic. The pandemic has highlighted significant developing robust processes that can stand the differences between public worldviews, including test of scientific scrutiny and peer review. But the populations who are skeptical of science and distrust pandemic has highlighted that scientific rigor is not governments and health systems. Within this climate, synonymous with public confidence. Elements of the HTA depends on public confidence for its funding and public, including some stakeholders, may have no the implementation of its recommendations or advice. awareness or connection to the scientific principles, For its credibility and legitimacy, its processes should processes, methods and institutions esteemed in the be seen as fair and transparent. But HTA is typically HTA community. HTA may be able to determine the only seen by a small subsection of the population who value of health technologies from pre-market approval have an interest in its assessments. Even among the to disinvestment, but can it find the shared values many stakeholders who may experience consequences necessary to foster and maintain public confidence? from HTAs, the process may not be visible resulting in misunderstandings or distrust about whose interests and This plenary will explore the nature of public confidence values are being considered or prioritized. and how it might influence how we reconceptualize HTA’s place in the lifecycle and our societies. It will Integrating stakeholders’ perspectives in HTA – either elicit different stakeholders’ experiences of integrating through evidence or participation – may play a role perspectives in HTA and challenge the community in improving public confidence in HTA by fostering to take a critical view of HTA’s contribution to public openness and transparency and increasing the relevance confidence in health and science. of HTA recommendations by ensuring they are informed by stakeholders. Despite many years of research to MODERATOR develop the field, in most jurisdictions its use and impact in HTA is unclear, and its relationship to scientific rigor is Ms. Heidi Livingstone unresolved. The task remains challenging. How should Senior Public Involvement Adviser, stakeholders’ perspectives be integrated transparently? Public Involvement Programme, NICE, How can competing needs and claims be managed? United Kingdom Which types of stakeholders are not included and what are the consequences of this lack of inclusivity? What Heidi is a Senior Public Involvement does public confidence look like, how should it be Adviser in the Public Involvement measured and to what extent can it be achieved? Programme (PIP) in NICE. She moved to the Public Involvement team in 2011 having joined NICE from the A lifecycle approach promises opportunities to address Health Development Agency in 2005 and had worked the disconnect between stakeholders, but may also increase the number and diversity of stakeholders and their perspectives as HTA collaboration crosses

FEATURE SESSIONS in the NHS since 1997. She is responsible for patient and published widely on new surgical techniques and their public involvement in medicines Health Technology introduction into surgical practice. He has over 600 Assessments work at NICE, specifically Technology publications in scientific journals. Appraisals and Highly Specialised Technologies, and has experience of working on Scientific Advice, The evaluation of new technologies and in particular Interventional Procedures, Medical Technologies and surgical technologies is another area of focus and Diagnostics. Heidi works with individual patients, carers, interest. Under his supervision, ASERNIP-S has been lay people and patient organisations who wish to get responsible for assessing these technologies before involved in the guidance, providing support, training and exposing the Australian population to them and has advice. She has led on different service evaluations of provided this service to the Australian and International patient participation in the technology appraisal process community for over 20 years. It is recognized nationally at NICE and provides training for patient groups as well and internationally as the premier surgical innovation as materials to help them participate in NICE. She works assessment group. with the Innovative Licensing and Access Pathway (ILAP) partner organisations (the Medicines and Healthcare He is Chair of the HTAi Asia Policy Forum, a past products Regulatory Agency, the Scottish Medicines President of HTAi and a past Chair of INAHTA. Consortium, the All Wales Therapeutics and &Toxicology Centre and NICE) on patient involvement in ILAP. SPEAKERS Heidi is a member of the HTAi Patient and Citizens Ms. Linda Daniels-van Saase Involvement Group steering group and works Manager Medisch-specialistische zorg, with colleagues internationally to improve patient Patiëntenfederatie Nederland, the involvement in HTAs, particularly in medicines HTAs. She Netherlands is one of the contributing authors in Patient Involvement in Health Technology Assessment, Springer, 2017(http:// Mrs. Linda Daniels-van Saase is a www.springer.com/gb/book/9789811040672) as well as Manager at the Netherlands Patients lead author on Evaluation of the impact of patient input Federation which represents more than 200 patient in health technology assessments at NICE (Cambridge organizations. Mrs. Daniels-van Saase studied law and University Press: 29 January 2021, e33). graduated in 1996 from the University of Amsterdam and has worked at the Dutch Institute of Healthcare. In Prof. Guy Maddern her previous role she was responsible for improving the Surgical Director Research & quality of care and reimbursement packages for patients. Evaluation (RAAS), Australia Dr. Alicia Granados Professor Guy Maddern is the RP Head of Global Rare Diseases Medical Jepson Professor of Surgery at the Scientific Advocacy, Sanofi Genzyme, University of Adelaide, Director of Spain Research at the Basil Hetzel Institute for Translational Health Research at The Queen Elizabeth Hospital Dr. Granados has an MD & Ph.D. in and Director and Surgical Research and Evaluation Public Health from the University of (incorporating ASERNIP-S) of the Royal Australasian Barcelona and is a specialist in respiratory medicine. College of Surgeons. He was trained at the University She is currently serving as Head of Global Rare Diseases of Adelaide and became a Fellow of the Royal Medical Scientific Advocacy at Sanofi Genzyme, where Australasian College of Surgeons in 1989. He has also she has been heading its global HTA strategy since 2021 and the former President of the Scientific Advisory

FEATURE SESSIONS Committee of AQuAS (Catalan Agency for Quality and and coordinator of Osteba -Osasun ebaluazioa-, HTA). Basque Office for Health Technology Assessment. He is currently the coordinator of the EU funded project Dr. Granados was responsible for creating and directing SAFENMEDTECH and coordinator of WP in the projects the Catalan Agency for Health Technology Assessment EXACT, INNO4COV, CAREMATRIX and HARMONICS. and Research (CAHTAR). She was a founding member He is the visiting director of HTA and Market Access at of INAHTA, the first international HTA network, and Health Cluster Network, performing different functions. the first HTA joint initiative in Europe, EUR-ASSESS, the He has been technical advisor of WHO on medical predecessor of EUnetHTA. She is also former President devices and HTA and universal coverage and has advised of the International Society for Technology Assessment or lectured on HTA in countries such as: Costa Rica, in Health Care (ISTAHC) and Chair of the Committee for Colombia, Malaysia, South Korea, Italy, Norway, Balkans the Creation of a new HTA Society: HTAi, of which she Region, Egypt, Tunisia, Mexico, China, Ghana, Brazil, was the first president. USA, Argentina, Vietnam, Singapur, Taiwan, among others. He is associate editor of HiNT and Frontiers in Dr. Granados has been the temporary advisor of several Pharmacology Journals and member of the editorial UN agencies on Evidence-Based Health Care and Acting board at IJTAHC and Health Policy. Regional Advisor of the WHO European Office, leading the Health Evidence Network. She has been an Associate Dr. Claudia Wild Professor of Medicine at the University of Barcelona and Managing Director (Geschäftsführung), has published more than 60 scientific and policy articles. HTA Austria, Austria Dr. Granados is former President of the Autonomous University of Barcelona’s Board of Trustees, Advisor to Dr. Claudia Wild is the Chief Executive the Catalan Government President on wellness and Officer (CEO) of AIHTA GesmbH economic reactivation and growth (CAREC), and the since 2020. Previously she was the Department of Health Advisory Council of Catalan Director of the LBI-HTA since its establishment in 2006. Government. She is currently serving voluntarily as Chair From 1989-2006 she worked as a Senior Researcher at of the HTAi Policy Forum Series Advisory Committee. the Institute of Technology Assessment at the Austrian Academy of Sciences and helped develop the research Dr. Iñaki Gutiérrez-Ibarluzea field Health Technology Assessment in Austria. She Director of Innovation, BIOEF, Spain studied communications & psychology at the University of Vienna and political sciences at the Ohio University Dr. Gutiérrez-Ibarluzea has a BSc and in Athens/Ohio/USA and completed her studies with a MSc in Sciences from the University of Graduation at the University of Vienna as a Doctor of the Basque Country UPV-EHU, Doctor Philosophy in 1985. In 2009, she habilitated in social in Sciences (NeuroScience) from medicine (Medical University Graz) on the topic of the same university, Masters in Epidemiology from the “resource allocation in health-care systems.” Dr. Wild is a Universidad de Granada and the Andalusian School of member of numerous expert panels providing advice on Public Health and Masters in Bioethics from Blanquerna health policy. - Universitat Ramon Llull and the Borja Vilaseca Institute of Bioethics. Past-President of HTAi (2021-2023) and President (2019-2021). He is the current president of i-HTS - International HealthTechScan, the Head of Knowledge Management and Evaluation of the Basque Foundation for Health Innovation and Research (BIOEF),

FEATURE SESSIONS Tuesday, June 28 HTA institutionalization along with the legislative introductions of mandatory HTA and development of Special Session: HTA in Challenging MEA (Managed Entry Agreements). Times: Experience in Ukraine Besides her full time work at SAFEMed, Rabia is the 09:25 – 09:35, Beatrix Theatre (Ground current Vice President of HTAi (2021-2023) and has Floor) been an active member of HTAi for many years, serving on the Board of Directors as ex officio (2013-2014), The war in Ukraine has challenged the country and Director (2014-2017) and re-elected Director (2017- the world continues to witness the heroism of a nation 2020). trying to protect its homeland. Dr. Oresta Piniazhko While the healthcare system in Ukraine has been under PhD, Director of HTA Department attack, the Ukrainian Ministry of Health continues to at State Expert Centre of Ministry of make enormous efforts to provide healthcare to people Health, Ukraine in need. Oresta is an experienced expert in HTA, pharmaceutical Since 2020, HTA has been mandatory for all medicine policy and implementation practitioner. She holds a coverage decisions and HTA is now well institutionalized PhD degree in Pharmacoeconomics and is currently in Ukraine. The war has challenged the function, but the holding a position of Director of HTA Department at Department has shown resilience to continue working the State Expert Center of the Ministry of Health of and supporting the health care decisions to be HTA- Ukraine, ensuring management and implementation of based despite the ongoing war. the best international practices of HTA into health care system of Ukraine since February 2019. Being a dynamic This short session will cover the challenges the communicator, she is also a President of Ukraine ISPOR Ukrainian HTA function faces and how they are Chapter since 2017 and before ISPOR Ukraine Students overcoming them. Network (2015-2017). Oresta is visiting lecturer at The Institute of Business Education of Vadym Hetman Kyiv Dr. Rabia Kahveci National Economics University, Danylo Halytskyi Lviv Senior Technical Advisor for National Medical University. Pharmaceutical Policy and Governance, SAFEMed project, Ukraine Rabia Kahveci is Senior Technical Advisor for Pharmaceutical Policy and Governance in the SAFEMed project, in Kyiv Ukraine since October 2018. SAFEMed project is a USAID funded and MSH led project that supports Ukrainian government. SAFEMed applies health system strengthening best practices to create evidence-based interventions and strengthen Ukraine’s pharmaceutical system. Her area of responsibility is to support priority setting and HTA, including and beyond capacity building and HTA institutionalization in Ukraine. Ukraine sets an excellent example of a LMIC with a recent rapid

FEATURE SESSIONS Wednesday, June 29 world data. Since 2012, he has directed a major project to support the development and updating of evidence- David Banta Tribute and Distinguished based clinical practice guidelines using the rigorous Career Award Presentation GRADE methodology for the U.S. Veterans Health Administration and Department of Defense, including 08:45 – 09:15, Beatrix Theatre (Ground more than 40 original and updated guidelines on 24 Floor) diverse clinical topics, including in chronic disease, mental and behavioral health, pain management, We’d love to hear from you and include your women’s health, rehabilitation, and military-related recollections in a memory book to be collated and conditions. bound following the Annual Meeting. A founding member of HTAi, Cliff has served on its Put your memories and thoughts on paper for us to Board, as its president (2011-13), and on numerous share after the meeting. In-person - visit booth 18 in committees for many years through the present. Cliff Expo Hall or virtually. has attended all annual meetings of HTAi and the predecessor society, ISTAHC, since their inception. AWARD PRESENTER: Since the 1990s, he has presented the introductory Dr. Wija Oortwijn, the Netherlands course, HTA 101, to hundreds of attendees of annual meetings of ISTAHC and HTAi. 2022 DAVID BANTA DISTINGUISHED CAREER AWARD RECIPIENT: He served as Chair of the Medicare Evidence Dr. Clifford Goodman Development & Coverage Advisory Committee (MEDCAC) for the U.S. Centers for Medicare and Clifford Goodman, PhD, is a Senior Medicaid Services (2009-2012). He is a Fellow of Vice President at The Lewin Group, the American Institute for Medical and Biological a health care policy consulting Engineering (AIMBE). firm based in the Washington, DC, metropolitan area. The Lewin Group is a unit of Optum, Cliff is an internationally recognized health policy issues a major subsidiary of UnitedHealth Group. moderator and facilitator of symposia, expert panels, advisory boards, and focus groups, having conducted Cliff has more than 30 years of experience in such hundreds of such events in recent years. areas as health technology assessment, evidence- based health care, comparative effectiveness research, Cliff earned a PhD from The Wharton School of the clinical practice guidelines, health economics, and University of Pennsylvania, a Master of Science from The studies pertaining to health care innovation, regulation, Georgia Institute of Technology, and a Bachelor of Arts access, and payment. He directs studies and projects from Cornell University. for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; health care provider institutions; and professional, industry, and patient advocacy groups. Cliff’s recent work has involved such areas as chronic disease, infectious disease, cancer, rare diseases, diagnostic testing, pharmacogenomics, gene therapy, biosimilars, value frameworks, value-based contracting, social determinants of health, and applications of real-

FEATURE SESSIONS Wednesday, June 29 processes or with coverage with evidence development requirements. Plenary 3 The following topics will be specifically addressed in the 11:10 – 12:45, Beatrix Theatre (Ground plenary: Floor) 1. How are different types of effectiveness Running Around in Circles; Time for Real evidence perceived by regulators, HTA bodies/ Collaboration between Regulators, HTA payers and clinicians over the lifecycle of health Bodies and Clinicians technologies? Regulators, HTA bodies/payers but also clinicians 2. What are experiences in terms of interaction and their guideline organizations, may provide between regulators, HTA bodies/payers and recommendations regarding (cost-)effectiveness of clinicians and how could these be implemented health technologies that have a large influence on the for different types of health technologies such as access to these technologies. Their recommendations medical devices and pharmaceuticals? may not always closely align which might lead to hampered and delayed access to these health 3. How do other stakeholders such as innovators technologies and uncertainty for patients. However, and patients perceive this interaction between the remit of those organizations may vary to a large regulators, HTA bodies/payers and clinicians, what extent over the lifecycle of a health technology. To is in it for them in different settings around the what extent do we wish for more alignment of their globe? recommendations, for instance, if the same data are used to evaluate clinical effectiveness? Or do we value This third plenary will explore the impact of regulators, the different roles of those stakeholders to ensure a HTA bodies and clinicians on the quality and efficiency cautious balance between quality, affordability, and of healthcare by focusing on their clearly laid out roles, accessibility of healthcare? How do innovators that their interaction and alignment of their processes. It will develop new health technologies experience these use the experiences of innovators and patients to assess different roles of those stakeholders and see their this impact and the interaction of these regulators, HTA differences as barriers or enablers for their innovations bodies and clinicians. to come to patients? MODERATOR This plenary will also include a discussion on the role of clinical practice data to improve our knowledge Dr. Laura Sampietro-Colom on the effectiveness and cost-effectiveness of health VP HTA & Access Policy, Johnson & technologies, such as pharmaceuticals, medical devices, Johnson, UK and digital health (including AI) and how different types of data and evidence can be efficiently collected, used, Dr Laura Sampietro-Colom is the and shared between those stakeholders at the different Deputy Director of Innovation and stages of the lifecycle. In the plenary, specific disease Head of the Health Technology areas in which the collaboration on the collection and Assessment (HTA) Unit at the Hospital Clinic of analyzing of data may be flourishing such as cardiology, Barcelona, a high-tech hospital and a reference for oncology (ATMPs such as CAR-T) and rare diseases, health care, research, innovation and medical training maybe highlighted. Further, emphasis may be placed in Spain. In her everyday work she supports clinicians on therapies approved through accelerated regulatory to prove the value for their clinical practice of both health care technologies they are developing and new 53

FEATURE SESSIONS technologies candidate to be introduced in the Hospital. of London (2007), a fellow of the Royal College of She is also active in different national and international Physicians of Edinburg (2017) and honorary Professor, initiatives around Innovative Public Procurement. She London School of Hygiene and Tropic Medicine (2020 is member of the advisory board of the EIT Health High Value Care Forum. She was the Project Leader of the Professor Alan Fraser EU Project Adopting Hospital based Health Technology Consultant Cardiologist and Scientific Assessment (AdHopHTA; 7th Framework Program). She Coordinator CORE-MD, University was President of the International Society for HTA (HTAi) Hospital Wales, United Kingdom and Chair of its Global Policy Forum and founder and Chair of the Latam Policy Forum. She was one of the Dr. Alan Fraser is a Consultant founders, and scientist, of the Catalan Agency for Health Cardiologist at the University Hospital Technology Assessment (nowadays AQuAS). During all of Wales, Cardiff, UK; Visiting Professor in Cardiovascular these years, her work has focused on the development, Imaging and Dynamics at the University of Leuven, identification, management and transfer of information Belgium; and Emeritus Professor of Cardiology at the to advise, public and private organizations, on designing Wales Heart Research Institute, Cardiff University. He strategies and policies for developing and adopting is a Past-President of the European Association of innovative technologies. Cardiovascular Imaging. He chairs the Regulatory Affairs Committee of the Biomedical Alliance in Europe and SPEAKERS is the Scientific Coordinator of the EU Horizon 2020 CORE-MD project (Coordinating Research and Evidence Dr. Peter Arlett for high-risk Medical Devices). His research interests Head, Data Analytics & Methods, include cardiac imaging, heart valve disease, heart European Medicines Agency, the muscle disease, and the pathophysiology and diagnosis Netherlands of heart failure. Dr. Arlett is the Head of the Data Dr. Javier Guzman Analytics and Methods Task Force Director, Global Health Policy, Center (March 2020 – present). Previously, he was the Head for Global Development, Colombia of Pharmacovigilance and Epidemiology Department, European Medicines Agency (2013–2020), Head of Javier Guzman is the Director of Pharmacovigilance and Risk Management Sector, Global Health Policy and a Senior European Medicines Agency (2008-2013, Principal Policy Fellow at the Center for Global Administrator, Pharmaceuticals Unit, European Development. Previously, he was Commission (2003-2008), UK delegate to the the Technical Director of the USAID-funded Medicines, European Committee for Human Medicinal Products Technologies, and Pharmaceutical Services (MTaPS) (CHMP) (2001-2003), Specialist Assessor and Manager, Program at Management Sciences for Health (MSH), Medicines Control Agency (now MHRA) (1996-2001) and helping over 20 governments in Africa and Asia build Hospital Physician, UK NHS: UCL, Oxford, Hammersmith their health system to ensure sustainable access to (to 1996). and appropriate use of safe, effective, quality-assured, and affordable medicines and pharmaceutical services. In addition to his medical degree from University Between 2013 and 2018, he played different roles within College London (UCL) (1991), Dr. Arlett has been a the Colombian government, first as Deputy Director member of the Royal College of Physicians (MRCP) of of the health technology assessment agency, then as London (1994), a fellow of the Faculty of Pharmaceutical Medicine (FFPM) of the Royal College of Physicians

FEATURE SESSIONS Director of Medicines and Health Technologies at the Dr Kubala Havrdová’s research interests include Ministry of Health and finally, as Director-General of the cytokine, immunoglobulin & T-cell research in multiple Colombian Food and Drug Surveillance Institute, one sclerosis, treatment of malignant MS. She created of the eight National Regulatory Authorities of regional “freedom from disease activity” concept used now to reference in the Americas. compare efficacy of MS drugs. She has published more than 150 publications on multiple sclerosis including Javier has worked as a physician, researcher, analyst Neuroimmunology, Multiple Sclerosis, Handbook on MS and policymaker in the United States, the United for General Practitioners, Pharmacotherapy of MS, and Kingdom, Australia, and his native Colombia. He is several books for patients. interested in how global health challenges such as Covid and antimicrobial resistance, can offer a window of She organized ECTRIMS Congress in Prague in 2007, is opportunity to improve the efficiency and effectiveness a member of MSIF International Medical and Scientific of global institutions and build more sustainable and Board, and member of the Czech Neurological Society equitable health systems. Committee. She introduced disease modifying treatment in MS in Czech Republic and established a network of As Director of Research for global health non- MS Centers covering all the country. She developed governmental organizations in the United Kingdom and Standards of Diagnostics and Treatment of MS and NMO Australia, he managed portfolios of health consulting in Czech Republic. and research projects focusing on pharmaceutical policy, pharmaceutical systems strengthening, and Professor Dana Horakova diseases that disproportionately affect low- and middle- Dept. of Neurology and Center income countries. for Clinical Neuroscience, Czech Republic In addition to his medical degree, Javier has an MSc in Health Policy, Planning and Financing from the London Prof. Dana Horakova, MD, graduated School of Economics and Political Science and the from the Faculty of Medicine of London School of Hygiene and Tropical Medicine and an Charles University in 1992. Since 1999 she has worked MBA (Executive) from the Australian Graduate School of at the MS Centre of the 1st Faculty of Medicine of Management. Charles University in Prague. In 2006 she completed a six-month internship at BNAC in Buffalo, USA. In 2010 Professor Eva Havrdova she received her Ph.D. degree with the thesis “Predictive Department of Neurology and Center markers for clinical development in MS patients.” for Clinical Neuroscience, Charles University, Czech Republic Dr. Horakova is a member of the Immunology Committee of the Czech Neurological Society and serves as a Dr Eva Kubala Havrdova is Professor scientific guarantor of the Czech national ReMuS registry. of Neurology at the First Faculty of She was the Chair of the MSBase Scientific Leadership Medicine, General University Hospital, Charles University Group from 2014 to 2020 and is currently a member of in Prague, Czech Republic. the SLG and a member of the MSBase Advisory Board. She obtained her medical degree at the same university Her key research interests include - markers of disease in 1981 and went on to specialize in neurology and activity and treatment response (clinical and MRI, became Professor at Charles University in 2010. She especially implementation and validation of quantitative is currently Director of the Center for Demyelinating volumetric MRI techniques into routine clinical practice) Diseases at Charles University, Prague. and the use of databases and registries in MS.

FEATURE SESSIONS Mrs. Ivett Jakab a focus on value-based healthcare and health system Patient advocate, EUPATI Fellow, strengthening. Hungary Dr. Steven Pearson She has been volunteering for local President, ICER, United States patient organizations in the field of organ transplantation since 2011. Steven D. Pearson, MD, MSc is She graduated from the European the Founder and President of the Patients’ Forum (EPF) Summer Training for Young Patient Institute for Clinical and Economic Advocates (STYPA) program in 2018 and supported Review (ICER). Dr. Pearson is also a the 2019 edition as a team leader. She joined the EPF Lecturer in the Department of Population Medicine at Youth Group in 2019 and lead the group as President Harvard Medical School. until 2022 working to strengthen the young patients’ voice throughout Europe. She is a EUPATI Fellow who An internist, health services researcher, and ethicist, Dr. graduated in 2021 and a member of the EUPATI Board of Pearson has served in many advisory and leadership Trustees. Her research interests are in the evolving areas roles in academia and government. In 2004 he of HTA and patient engagement in healthcare decision- was awarded an Atlantic Fellowship from the British making. Her mission is to bring the perspectives of Government and chose to serve as Senior Fellow at different stakeholders in healthcare closer together. the National Institute for Health and Clinical Excellence (NICE). Returning to the United States in 2005 he was Ivett is a patient herself; she had an acute liver transplant asked to serve during the George W. Bush Administration in 2008 due to a rare genetic disorder called Wilson’s as Special Advisor, Technology and Coverage Policy, at disease. the Centers for Medicare and Medicaid Services, and also accepted an appointment as Visiting Scientist in Dr. Christine Muzel the Department of Bioethics at the National Institutes Director, Technology Strategy, Philips, of Health, a position he maintained from 2005-2019. In Belgium other roles, Dr. Pearson has also served as the Vice Chair of the Medicare Evidence Development and Coverage Mrs. Muzel leads the integration of Advisory Committee (MedCAC). health economics and market access strategies into the innovation-to- Dr. Pearson’s publications include over 150 peer- market process, with a focus on the evidence necessary reviewed articles and commentaries on the role of to prove value to providers, payers, patients, and health evidence in the health care system, and the book No technology assessment bodies in the rapidly changing Margin, No Mission: Health Care Organizations and landscape of health care. the Quest for Ethical Excellence, published by Oxford University Press. She brings extensive international experience in Medtech start-ups, business ventures and global corporations, spanning technology and go-to-market strategy, product management, sales, market access and reimbursement for innovative health technologies. She holds an M.A. in business studies and humanities, a diploma in health economics, and an Executive MBA in Healthcare Management, Financing and Policy, with

FEATURE SESSIONS Wednesday, June 29 JILL SANDERS MEMORIAL SCHOLARSHIP Closing Ceremony and Presentation AWARD of Awards Award Presenter: 12:45 – 14:00, Beatrix Theatre (Ground • Rabia Kahveci, Ukraine Floor) HTAI EDUCATIONAL SCHOLARSHIP AWARD HTAi ANNUAL MEETING PRESENTATON AWARDS Award Presenter: • Rabia Kahveci, Ukraine • B est Oral Presentation • Best Student Oral Presentation SIGRID DROSTE ETHICS AWARD • Best Poster • Best Student Poster Award Presenter: Award Presenters: • Dr. Alric Rüther, Germany • Dr. Wim Goettsch, Netherlands • Ms. Ann Single, Australia Introduction to HTAi 2023 Annual Meeting, in • Professor Gert Jan van der Wilt, Netherlands Adelaide, Australia, June 23 to 28, 2023 INTERNATIONAL JOURNAL OF TECHNOLOGY • Professor Brendon Kearney, Australia ASSESSMENT IN HEALTH CARE (IJTAHC) • Professor Guy Maddern, Australia AWARDS Closing Remarks EGON JONSSON AWARD Foreword from Professor Egon Jonsson • Dr. Wija Oortwijn, HTAi President, Netherlands Award Presenter: • Wija Oortwijn, Netherlands BEST REVIEWER AWARD Award Presenter: • Wendy Babidge, Australia This year, HTAi awarded a total of 42 Participation Grants to 13 patients and patient representatives, 23 residents of lower or middle-income countries, and 6 students. We would like to thank our Participation Grant Sponsors for their generous support.

Online MSc Health Technology Assessment Want to be a 21st century HTA practitioner? Students can study to Certificate, Diploma or Masters Governments around the world are increasingly using (includes a research project) level. Health Technology Assessment (HTA) to inform decision- For more details please visit making. Join our online distance learning programme www.gla.ac.uk/hta and enhance your career by acquiring quantitative and qualitative research skills in support of HTA. Continuous Professional Development (CPD) The course is taught via video presentations by teaching Our CPD programme includes our new live, online course faculty, live online lectures, weekly exercises, directed Maximising the Value of Clinical Trial Data: Advanced readings and student/faculty interaction on discussion Analysis for Economic Evaluation and Modelling. In forums. addition, the online MSc HTA courses listed above can be taken as non-accredited CPD. They run at the same time Our MSc comprises three core courses: as the MSc courses so please visit • HTA: Policy and Principles www.gla.ac.uk/hta for more details of dates. • Statistical Methods for HTA and Evidence-Based Medicine Contact us: • Health Economics for HTA • Research Project Health Economics and Health Technology (core ‘course’ only for MSc level) Assessment (HEHTA) 1 Lilybank Gardens, Glasgow G12 8RZ Students may then select from a range of optional Tel: +44 (0)141 330 4010 courses: Website: www.gla.ac.uk/hehta Twitter: @HEHTAGlasgow • Outcome Measurement and Valuation for HTA LinkedIn: www.LinkedIn.com/company/hehta • Qualitative Research Methods for HTA • HTA in a Global Context • Survival Analysis for HTA • Decision Analytical Modelling and Early HTA • Data Science • Evidence Synthesis • Choice Experiments for Health Economics • Maximising the Value of Clinical Trial Data: Advanced Analysis for Economic Evaluation and Modelling © University of Glasgow 2022. The University of Glasgow, charity number SC004401 27/05/2022 09:28 HEHTA Online Health Technology Advert.indd 1

WORKSHOPS Workshops 59

WORKSHOPS Workshops Saturday, June 25 2022 WS01 Advanced Workshop in Information Retrieval: WS05 HTA 101: Introduction to Health Technology Addressing Lifecycles of the Literature in Health Assessment Technology Assessment 08:30 - 12:00, Room 315 08:30 - 12:00 & 13:00 - 16:00, Room 114 Speakers: Cliff Goodman, USA Speakers: Christa Niehot, Netherlands Mbachi Ruth Msomphora, Norway Per-Olov Andersson, Sweden WS18 Lifecycle Approach to Regulatory, James Thomas, UK Management and Assessment of Health Siw Waffenschmidt, Germany Technologies: Is it the Solution for Resource Amanda Hodgson, Canada Constraint Settings? Monika Mierzwinski-Urban, Canada David Kaunelis, Canada 13:00 - 16:30, Room 215 Stacy Brody, USA Nicole Askin, Canada Speakers: Jani Mueller, South Africa Mark Mueller, Canada Joseph T Matthew, India Ingrid Harboe, Norway WS02 How to Incorporate Environmental Impact to Quality of Care and Guidelines 08:30 - 12:00, Room 117 Speakers: Ayla Lokhorst, Netherlands Pauline de Heer, Netherlands Iris Wichers, Netherlands WS03 How to Perform a Trial-Based Economic Evaluation Using R 08:30 - 12:00, Room 215 Speakers: Johanna Van Dongen, Netherlands Judith Bosmans, Netherlands Angela Jornada Ben, Netherlands Mohamed El Alili, Netherlands

WORKSHOPS WS18 Lifecycle Approach to Regulatory, Sunday, June 26, 2022 Management and Assessment of Health Technologies: Is it the Solution for Resource WS10 Research Oriented Market Access for Constraint Settings? Adopting High Cost Therapies – Principles and Practice 13:00 - 16:30, Room 215 Speakers: Jani Mueller, South Africa 08:30 - 12:00, Room 315 Joseph T Matthew, India Speakers: Jeff Round, Canada Erin Kirwin, Canada WS06 An Interactive Workshop on the Theory Ken Bond, Canada and Practice of Measuring the Impact of Health Technology Assessment WS11 Early Awareness and Alert Systems (EAA) on New, Emerging and Obsolete Technologies 13:00 - 16:30, Room 315 Speakers: Matthias Perleth, Germany 08:30 - 12:00, Room 110 Chantal Guilhaume, France Jeff Round, Canada Speakers: Iñaki Gutierrez-ibarluzea, Spain Catherine Truchon, Canada Rosmin Esmail, Canada Patrice Chalon, Belgium Maximilian Otte, Germany Hans-Peter Dauben, Germany WS07 Generating and Using Real World Evidence for Brendon Kearney, Australia Health Technology Assessment Anne-Lien Espeland, Norway 13:00 - 16:30, Room 417 WS12 Values In Doing Assessments Of Healthcare Technologies (VALIDATE) Massoud Toussi, France Speakers: Elena Petelos, Netherlands Dimitra Lingri, Greece 08:30 - 12:00, Room 117 Speakers: Gert Jan van der Wilt, Netherlands Faye Freriks, Netherlands WS08 Integrating Patient and Citizen Perspectives: Payam Abrishami, Netherlands Resources and Challenges for a Lifecycle Approach Ann Single, Australia Bart Bloemen, Netherlands 13:00 - 16:30, Room 117 Speakers: Ann Single, Australia Niel Bertelsen, Germany Anke Holtorf, Switzerland Hedi Livingston, Netherlands Aline Silva, Canada